Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.

[1]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[3]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[4]  M. Hung,et al.  Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer , 2004, Cancer Gene Therapy.

[5]  Hiroyuki Honda,et al.  Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. , 2004, Cancer letters.

[6]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[7]  Naoto T. Ueno,et al.  P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.

[8]  Ramaswamy Nilakantan,et al.  Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.

[9]  Gordon B Mills,et al.  Lineage Infidelity of MDA-MB-435 Cells , 2004, Cancer Research.

[10]  M. Gore,et al.  A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene , 2004, Clinical Cancer Research.

[11]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[12]  R. Bast,et al.  Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression* , 2004, Journal of Biological Chemistry.

[13]  J. Garcia-conde,et al.  Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Gelmon,et al.  Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model , 2004, Cancer biology & therapy.

[15]  K. Garber.  Improved Paclitaxel formulation hints at new chemotherapy approach. , 2004, Journal of the National Cancer Institute.

[16]  B. Groner,et al.  Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2 , 2003, Breast Cancer Research and Treatment.

[17]  E. Chang,et al.  HER‐2‐Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents , 2003, Annals of the New York Academy of Sciences.

[18]  K. Bloom,et al.  HER-2/neu testing in breast cancer. , 2003, American journal of clinical pathology.

[19]  G. Hortobagyi,et al.  Neoadjuvant chemotherapy for breast carcinoma , 2003, Cancer.

[20]  Terry L. Smith,et al.  ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up‐regulation and tyrosine‐15 hyperphosphorylation of p34Cdc2 , 2003, Cancer.

[21]  K. Mayne,et al.  672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer , 2003 .

[22]  R. Bast,et al.  The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition* , 2003, Journal of Biological Chemistry.

[23]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[24]  K. Tanabe,et al.  Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. , 2003, International journal of oncology.

[25]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[26]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[27]  A. Berezov,et al.  Antibody like peptidomimetics as large scale immunodetection probes. , 2003, Cellular and Molecular Biology.

[28]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[29]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[30]  V. Chinchilli,et al.  Decreased Response to Paclitaxel Versus Docetaxel in HER-2/neu Transfected Human Breast Cancer Cells , 2003, American journal of clinical oncology.

[31]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[32]  Mitchell D Schnall,et al.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.

[33]  M. Hung,et al.  Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. , 2002, Cancer research.

[34]  G. Hortobagyi,et al.  Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. , 2002, Cancer research.

[35]  A. Berezov,et al.  Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics* , 2002, The Journal of Biological Chemistry.

[36]  E. Chang,et al.  Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels , 2002, Molecular medicine.

[37]  W. Wilmanns,et al.  Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy , 2002, Tumor Biology.

[38]  J. Bergh,et al.  C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. , 2002, European journal of cancer.

[39]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[40]  G. Hortobagyi,et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Kaku,et al.  Increased Sensitivity to Cisplatin in Gastric Cancer by Antisense Inhibition of the HER-2/neu (c-erbB-2) Gene , 2001, Chemotherapy.

[42]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[43]  T. K. Yeung,et al.  Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. , 2000, Biochemical and biophysical research communications.

[44]  Martin R. Johnson,et al.  A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  M. Hung,et al.  Role of erbB2 in breast cancer chemosensitivity. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[46]  B. Lloveras,et al.  Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  R. Stein,et al.  Evolutionary Analysis of the ErbB Receptor and Ligand Families , 2000, Journal of Molecular Evolution.

[48]  G. Tortora,et al.  Resistance to taxanes is induced by c‐erbB‐2 overexpression in human MCF‐10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A , 2000, International journal of cancer.

[49]  Donald M. O'Rourke,et al.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo , 2000, Nature Biotechnology.

[50]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[51]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[52]  G. Hortobagyi,et al.  Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  Jun Yao,et al.  Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.

[54]  R. Finn,et al.  Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.

[55]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Dittrich,et al.  Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. , 1998, British Journal of Cancer.

[57]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[58]  J. Isola,et al.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British Journal of Cancer.

[59]  S. Dickman.  Antibodies Stage a Comeback in Cancer Treatment , 1998, Science.

[60]  G. Hortobagyi,et al.  Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol , 1998, Oncogene.

[61]  A. Vincent-Salomon,et al.  No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer , 1998, International journal of cancer.

[62]  T. Fehm,et al.  The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer , 1997, Oncology.

[63]  M. Hung,et al.  Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A , 1997, Oncogene.

[64]  R. Finn,et al.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.

[65]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[66]  Dihua Yu,et al.  Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.

[67]  M. Hung,et al.  Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. , 1996, Oncogene.

[68]  D. Curiel,et al.  Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[70]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[72]  M. Hung,et al.  Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. , 1995, Oncogene.

[73]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[74]  C. Gao,et al.  Induction of cyclin B and H1 kinase activity in apoptotic PC12 cells. , 1995, Experimental cell research.

[75]  C. Shapiro,et al.  Treatment of metastatic breast cancer: present and future prospects. , 1995, Seminars in oncology.

[76]  G. Finocchiaro,et al.  Mutation rate of the CDKN2 gene in malignant gliomas. , 1994, Cancer research.

[77]  F. Ciardiello,et al.  Induction of multidrug resistance (MDR) by transfection of MCF‐10A cell line with c‐Ha‐ras and c‐erbB‐2 oncogenes , 1994, International journal of cancer.

[78]  D. Curiel,et al.  Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. , 1994, Gene therapy.

[79]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[80]  M. Lippman,et al.  Overview of the biologic markers of breast cancer. , 1994, Hematology/oncology clinics of North America.

[81]  P. Carroll,et al.  Heterogeneity of erbB-2 gene amplification in bladder cancer. , 1993, Cancer research.

[82]  G. Nicolson,et al.  Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. , 1992, Oncogene.

[83]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[85]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  K. Sugimachi,et al.  Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.

[87]  N. Lemoine,et al.  Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. , 1991, British Journal of Cancer.

[88]  M. Hung,et al.  Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene , 1991, Molecular and cellular biology.

[89]  G. Stenman,et al.  Expression of the ERBB2 protein in benign and malignant salivary gland tumors , 1991, Genes, chromosomes & cancer.

[90]  M. Hung,et al.  Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[91]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[92]  B. Seliger,et al.  Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines , 2004, International journal of cancer.

[93]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[94]  A. Al Moustafa,et al.  The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[95]  R. Weinberg,et al.  Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. , 1986, Proceedings of the National Academy of Sciences of the United States of America.